VISUAL OUTCOME AFTER INTRAVITREAL BEVACIZUMAB (AVASTIN) IN THE TREATMENT OF BRANCH RETINAL VEIN OCCLUSION

Objective: To evaluate the visual outcome after intravitreal injection of bevacizumab (Avastin) in patients with branch retinal vein occlusion. Study Design: Prospective study. Place and Duration of Study: Combined Military Hospital (CMH) Kharian, from Mar 2016 to Nov 2017. Material and Met...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Saquib Naeem, Abdul Rafe
Formato:	article
Lenguaje:	EN
Publicado:	Army Medical College Rawalpindi 2019
Materias:	avastin bevacizumab branch retinal vein occlusion intravitreal injections vascular endothelial Medicine R Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/75470a3f2773428ba3924d4257aaa3b9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:75470a3f2773428ba3924d4257aaa3b9
record_format	dspace
spelling	oai:doaj.org-article:75470a3f2773428ba3924d4257aaa3b92021-11-12T07:16:14ZVISUAL OUTCOME AFTER INTRAVITREAL BEVACIZUMAB (AVASTIN) IN THE TREATMENT OF BRANCH RETINAL VEIN OCCLUSION0030-96482411-8842https://doaj.org/article/75470a3f2773428ba3924d4257aaa3b92019-04-01T00:00:00Zhttps://www.pafmj.org/index.php/PAFMJ/article/view/2761/2166https://doaj.org/toc/0030-9648https://doaj.org/toc/2411-8842Objective: To evaluate the visual outcome after intravitreal injection of bevacizumab (Avastin) in patients with branch retinal vein occlusion. Study Design: Prospective study. Place and Duration of Study: Combined Military Hospital (CMH) Kharian, from Mar 2016 to Nov 2017. Material and Methods: Patients of branch retinal vein occlusion (BRVO), were injected with minimum of one intravitreal bevacizumab 1.25 mg in 0.05 ml. Patients were examined using Snellen visual acuity testing, Fundus Fluorescein Angiography (FFA) and Optical Coherence Tomogragphy (OCT). Detailed eye examination was done before the procedure and follow-up visit on monthly basis was done for six months. Results: Twenty eight eyes of 28 patients were included, with a mean age of 63 years (SD 16.1). The patients received a mean of 3 (SD 1.30) injections of bevacizumab per eye. No adverse events were seen. At the baseline the mean central macular thickness was 559 microns which improved to 380 micron at 3rd month (p<0.001) and 300 microns after six months. The mean baseline acuity was log MAR = 0.70 (SD 0.19) and at three month log MAR=0.40 (SD 0.20); the difference was significant (p=0.001). At last follow-up of 6 months, the mean visual acuity was log MAR = 0.30 (SD 0.21), which was better than baseline (p<0.001). Twenty seven eyes showed improvement in visual acuity. Conclusion: Intravitreal bevacizumab caused substantial reduction in macular edema and enhancement in visual acuity. In this study the number of patients was limited and the follow-up was too short to makes recommendations of any specific treatment guidelines. Further studies are needed with long followup for treatment recommendations.Saquib NaeemAbdul RafeArmy Medical College Rawalpindiarticleavastinbevacizumabbranch retinal vein occlusionintravitreal injectionsvascular endothelialMedicineRMedicine (General)R5-920ENPakistan Armed Forces Medical Journal, Vol 69, Iss 2, Pp 391-396 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	avastin bevacizumab branch retinal vein occlusion intravitreal injections vascular endothelial Medicine R Medicine (General) R5-920
spellingShingle	avastin bevacizumab branch retinal vein occlusion intravitreal injections vascular endothelial Medicine R Medicine (General) R5-920 Saquib Naeem Abdul Rafe VISUAL OUTCOME AFTER INTRAVITREAL BEVACIZUMAB (AVASTIN) IN THE TREATMENT OF BRANCH RETINAL VEIN OCCLUSION
description	Objective: To evaluate the visual outcome after intravitreal injection of bevacizumab (Avastin) in patients with branch retinal vein occlusion. Study Design: Prospective study. Place and Duration of Study: Combined Military Hospital (CMH) Kharian, from Mar 2016 to Nov 2017. Material and Methods: Patients of branch retinal vein occlusion (BRVO), were injected with minimum of one intravitreal bevacizumab 1.25 mg in 0.05 ml. Patients were examined using Snellen visual acuity testing, Fundus Fluorescein Angiography (FFA) and Optical Coherence Tomogragphy (OCT). Detailed eye examination was done before the procedure and follow-up visit on monthly basis was done for six months. Results: Twenty eight eyes of 28 patients were included, with a mean age of 63 years (SD 16.1). The patients received a mean of 3 (SD 1.30) injections of bevacizumab per eye. No adverse events were seen. At the baseline the mean central macular thickness was 559 microns which improved to 380 micron at 3rd month (p<0.001) and 300 microns after six months. The mean baseline acuity was log MAR = 0.70 (SD 0.19) and at three month log MAR=0.40 (SD 0.20); the difference was significant (p=0.001). At last follow-up of 6 months, the mean visual acuity was log MAR = 0.30 (SD 0.21), which was better than baseline (p<0.001). Twenty seven eyes showed improvement in visual acuity. Conclusion: Intravitreal bevacizumab caused substantial reduction in macular edema and enhancement in visual acuity. In this study the number of patients was limited and the follow-up was too short to makes recommendations of any specific treatment guidelines. Further studies are needed with long followup for treatment recommendations.
format	article
author	Saquib Naeem Abdul Rafe
author_facet	Saquib Naeem Abdul Rafe
author_sort	Saquib Naeem
title	VISUAL OUTCOME AFTER INTRAVITREAL BEVACIZUMAB (AVASTIN) IN THE TREATMENT OF BRANCH RETINAL VEIN OCCLUSION
title_short	VISUAL OUTCOME AFTER INTRAVITREAL BEVACIZUMAB (AVASTIN) IN THE TREATMENT OF BRANCH RETINAL VEIN OCCLUSION
title_full	VISUAL OUTCOME AFTER INTRAVITREAL BEVACIZUMAB (AVASTIN) IN THE TREATMENT OF BRANCH RETINAL VEIN OCCLUSION
title_fullStr	VISUAL OUTCOME AFTER INTRAVITREAL BEVACIZUMAB (AVASTIN) IN THE TREATMENT OF BRANCH RETINAL VEIN OCCLUSION
title_full_unstemmed	VISUAL OUTCOME AFTER INTRAVITREAL BEVACIZUMAB (AVASTIN) IN THE TREATMENT OF BRANCH RETINAL VEIN OCCLUSION
title_sort	visual outcome after intravitreal bevacizumab (avastin) in the treatment of branch retinal vein occlusion
publisher	Army Medical College Rawalpindi
publishDate	2019
url	https://doaj.org/article/75470a3f2773428ba3924d4257aaa3b9
work_keys_str_mv	AT saquibnaeem visualoutcomeafterintravitrealbevacizumabavastininthetreatmentofbranchretinalveinocclusion AT abdulrafe visualoutcomeafterintravitrealbevacizumabavastininthetreatmentofbranchretinalveinocclusion
_version_	1718431116173508608

VISUAL OUTCOME AFTER INTRAVITREAL BEVACIZUMAB (AVASTIN) IN THE TREATMENT OF BRANCH RETINAL VEIN OCCLUSION

Ejemplares similares